Keith Regnante, CFO of Keros Therapeutics ($KROS), made one open market sale of shares in the last year, totaling $77,483. His most recent transaction occurred on February 18, 2026. Among 11,678 insiders with sales, his amount ranks 9,921st, below the average of 8.6 million per person across 6.4 transactions on average. He reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 24, 2026 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | CHIEF FINANCIAL OFFICER | A | Employee Stock Option (Right to Buy) | 60000 | $0.00 | 60,000.0000 | 41,202,371 | 9999.99% | 0.15% |
| Feb. 18, 2026 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | CHIEF FINANCIAL OFFICER | S | Common Stock | 4739 | $16.35 | 39,261.0000 | 41,202,371 | 10.77% | 0.01% |
| Feb. 18, 2025 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | CHIEF FINANCIAL OFFICER | A | Common Stock | 44000 | $0.00 | 44,000.0000 | 37,437,652 | 9999.99% | 0.12% |
| Jan. 4, 2024 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | CHIEF FINANCIAL OFFICER | S | Common Stock | 40000 | $45.29 | 0.0000 | 29,447,119 | 100.00% | 0.14% |
| Jan. 4, 2024 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | CHIEF FINANCIAL OFFICER | M | Common Stock | 40000 | $16.00 | 40,000.0000 | 29,447,119 | 9999.99% | 0.14% |
| Feb. 13, 2024 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | CHIEF FINANCIAL OFFICER | A | Employee Stock Option (right to buy) | 40000 | $0.00 | 40,000.0000 | 29,447,119 | 9999.99% | 0.14% |
| Jan. 4, 2024 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | M | Employee Stock Option (right to buy) | 40000 | $0.00 | 53,622.0000 | 29,447,119 | 42.73% | 0.14% |
| Nov. 4, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | M | Common Stock | 40000 | $16.00 | 40,000.0000 | 25,241,030 | 9999.99% | 0.16% |
| Nov. 4, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | S | Common Stock | 40000 | $45.29 | 0.0000 | 25,241,030 | 100.00% | 0.16% |
| June 9, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | S | Common Stock | 2579 | $47.25 | 0.0000 | 25,241,030 | 100.00% | 0.01% |
| June 9, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | M | Employee Stock Option (right to buy) | 20000 | $0.00 | 93,622.0000 | 25,241,030 | 17.60% | 0.08% |
| June 8, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | M | Employee Stock Option (right to buy) | 20000 | $0.00 | 113,622.0000 | 25,241,030 | 14.97% | 0.08% |
| June 9, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | S | Common Stock | 15993 | $45.03 | 4,007.0000 | 25,241,030 | 79.97% | 0.06% |
| June 9, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | M | Common Stock | 20000 | $16.00 | 20,000.0000 | 25,241,030 | 9999.99% | 0.08% |
| June 8, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | S | Common Stock | 2699 | $48.65 | 0.0000 | 25,241,030 | 100.00% | 0.01% |
| June 8, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | S | Common Stock | 17301 | $47.66 | 2,699.0000 | 25,241,030 | 86.51% | 0.07% |
| June 8, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | M | Common Stock | 20000 | $16.00 | 20,000.0000 | 25,241,030 | 9999.99% | 0.08% |
| June 9, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | S | Common Stock | 1428 | $46.46 | 2,579.0000 | 25,241,030 | 35.64% | 0.01% |
| Feb. 16, 2023 | Keros Therapeutics, Inc. | $KROS | Regnante Keith | Chief Financial Officer | A | Employee Stock Option (right to buy) | 40000 | $0.00 | 40,000.0000 | 25,241,030 | 9999.99% | 0.16% |